Lower GI 2017

Other trials randomising after CRT

TRIAL

Patient number

Primary endpoint

OS

DFS

HR for DFS

QUASAR

3239 overall 968 rectal 203 preop RT

all-cause mortality.

80% versus 83.4%

Not stated 0.78 CI [0.44- 1.22] ( p=0·004)

(92% stage II) PROCTOR SCRIPT

437

OS

5-year-OS 79·2% vs 80·4% (HR 0·93)

5-year-DFS 55·4%vs62·7 %(HR0·80)

0.80 CI [0.60- 1.07] (p=0·13).

GERCOR 357

DFS

OS HR =0.87 5-year DFS

0.80,

69% preop RT

58% vs 63%

(p=0.154)

Chronicle

113

DFS

3-year-OS 89% vs 88% (HR 1·18) 3-year-OS 86%vs95% (HR 0·46)

5-year DFS

0.80 (p=0.56)

71% vs 78%

ADORE 321

DFS

3-year DFS

0.63 (p=0.03)

63% vs 72%